Penbrook Management LLC Buys 21,000 Shares of Aquestive Therapeutics, Inc. $AQST

Penbrook Management LLC increased its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 93.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 43,585 shares of the company’s stock after buying an additional 21,000 shares during the period. Penbrook Management LLC’s holdings in Aquestive Therapeutics were worth $144,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. USAdvisors Wealth Management LLC bought a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth about $33,000. First National Bank & Trust Co. of Newtown bought a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth about $50,000. Everstar Asset Management LLC boosted its holdings in shares of Aquestive Therapeutics by 38.7% during the 1st quarter. Everstar Asset Management LLC now owns 300,000 shares of the company’s stock worth $870,000 after buying an additional 83,777 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 12.2% during the 1st quarter. AQR Capital Management LLC now owns 129,019 shares of the company’s stock worth $374,000 after buying an additional 14,025 shares during the period. Finally, DAFNA Capital Management LLC boosted its holdings in Aquestive Therapeutics by 11.8% in the 1st quarter. DAFNA Capital Management LLC now owns 142,000 shares of the company’s stock valued at $412,000 after purchasing an additional 15,000 shares during the period. Institutional investors own 32.45% of the company’s stock.

Insider Buying and Selling

In related news, insider Peter E. Boyd sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $5.30, for a total transaction of $79,500.00. Following the completion of the transaction, the insider directly owned 288,323 shares in the company, valued at $1,528,111.90. This represents a 4.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Barber sold 91,343 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $6.03, for a total transaction of $550,798.29. Following the sale, the chief executive officer directly owned 923,430 shares in the company, valued at $5,568,282.90. The trade was a 9.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 178,923 shares of company stock worth $1,006,598 in the last three months. 7.85% of the stock is owned by corporate insiders.

Aquestive Therapeutics Price Performance

AQST stock opened at $6.66 on Tuesday. The company has a 50 day simple moving average of $4.82 and a 200 day simple moving average of $3.73. The stock has a market cap of $664.14 million, a price-to-earnings ratio of -9.51 and a beta of 1.77. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $6.86.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on AQST. Oppenheimer boosted their price objective on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. JMP Securities boosted their price objective on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a report on Thursday. Zacks Research raised shares of Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 13th. Citigroup reissued an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.71.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.